Navinci

– pioneers of molecular tools with strong legacy

Navinci (formerly Olink Bioscience), has a proud history of inventing analytic technologies for nucleic acids and proteins, identifying commercial opportunities and bringing successful products to the market to serve scientists in research and drug development. First founded in 2004 on the breakthrough innovations by Professor Ulf Landegren and colleagues at Uppsala University, the company has directly marketed a wide range of products including the Duolink in situ protein detection product line, which was acquired by Sigma-Aldrich in 2016, and Proseek multiplex panels, now known as Olink Target and marketed by Olink Proteomics.

In 2016, Olink Bioscience became Navinci Diagnostics and split from Olink Proteomics, which is now focused on highly multiplexed protein biomarker analysis in the circulation to improve precision medicine and has recently been noted on Nasdaq NY.

Navinci has, in close collaboration with Uppsala University, continued to innovate the field of spatial biology with ground-breaking tools for studying the tissue microenvironment.

In 2020, Navinci launched the NaveniFlex product line, the next generation of proximity ligation assay, featuring our proprietary UnFold technology. We are now rapidly expanding our product range for the in situ detection of protein interactions and post-translational modifications, which are not possible to detect with standard techniques such as immunofluorescence and immunohistochemistry.

It is essential to understand protein functions and their interplay to be able to diagnose patients, develop efficient drugs, and treat with precision

Our vision is that scientists can fully understand protein interplay in tumors in order to bring precision medicine to the next level and save human lives

Navinci holds a broad and growing IP portfolio utilizing oligonucleotide-conjugated antibodies for the detection of proteins and their interactions. Besides the in-house products developed out of these innovations, IP has also been outlicensed to several leading international life science companies. Moreover, Navinci / Olink Bioscience has launched several daughter companies such as Olink Proteomics (noted on Nasdaq, New York), which develops high-throughput protein immunoassays, Q-linea (noted on Nasdaq), which focuses on counteracting antibiotic resistance in sepsis, and Halogenomics (acquired by Agilent), which focuses on target selection for next generation sequencing.